Associated Genetic Biomarkers
KANK1 is altered in 0.02% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, bladder urothelial carcinoma, colorectal neuroendocrine carcinoma, and conventional glioblastoma multiforme having the greatest prevalence of alterations .
The most common alterations in KANK1 are KANK1-NTRK3 Fusion (0.03%) and KANK1-DOCK8 Fusion (0.02%) .
KANK1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains KANK1 status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with KANK1 status in the inclusion eligibility criteria most commonly target adenocarcinoma of the gastroesophageal junction and gastric adenocarcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is KANK1 Expression .
Docetaxel and selumetinib are the most frequent therapies in trials with KANK1 as an inclusion criteria .
Significance of KANK1 in Diseases
Adenocarcinoma Of The Gastroesophageal Junction +
KANK1 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains KANK1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) .
Gastric Adenocarcinoma +
KANK1 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KANK1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.